BEAM-101 seems to be competitive with approved sickle cell treatments, William Blair analysts said in a note to investors, ...

BEAM-101 is an ex vivo genetic therapy delivered as part of an autologous haematopoietic stem cell transplant (HSCT) after a ...

Beam Therapeutics enrolls 35 patients in BEACON trial for BEAM-101 in sickle cell disease, with promising early safety and ...

The death, which investigators linked to a preparatory chemo treatment rather than Beam's medicine, highlights the risks of ...

Beam Therapeutics gave an initial look at the first handful of patients who received its experimental gene-edited treatment ...

Beam Therapeutics (NASDAQ:BEAM) fell sharply in the morning hours Tuesday after multiple media reports indicated that a patient has died following the administration of the company's experimental gene ...

BMO Capital says the first-ever clinical data from Beam Therapeutics (BEAM)’ base editing platform in sickle cell disease, or SCD, ...

The patient died four months after BEAM-101 infusion “due to respiratory failure that was determined by the investigator to ...

Initial Clinical Data for BEAM-101 and Preclinical Non-human Primate Data for ESCAPE Accepted for Presentation at American Society of Hematology ...

Analysts estimate that Beam Therapeutics will report an earnings per share (EPS) of $-1.16. The announcement from Beam Therapeutics is eagerly anticipated, with investors seeking news of surpassing ...

The Iron Beam, developed alongside the Iron Dome, is designed to neutralize a range of aerial threats, including missiles, ...

The Chief Executive Officer (CEO) of the Housing and Construction Mayor Limited, My-ACE China, has urged journalists in ...